HIGH DOSAGE OF ARIPIPRAZOLE INDUCED PRIAPISM: A CASE REPORT

To the Editor:

Priapism is a persistent erection, usually painful, that is not necessarily associated with stimulation or sexual desire. Priapism might caused by medical treatment provided from a clinical practice. There are some case reports about antipsychotic-related priapism.1 However, there are few reports about aripiprazole-induced priapism. We present a case of a patient who developed priapism during treatment with aripiprazole.

Mr. B, a 24 year-old male, is a case of psychotic disorder. He had idle daily life for four years. Four months ago, he started having auditory hallucination, delusion of being monitored, delusion of persecutory, bizarre delusion, and magical thinking. He was admitted to our acute psychiatry ward due to psychotic deterioration. We initially prescribed aripiprazole 10 mg/day. Nine days later we increased the dosage to 20 mg/day. After 8 days of this dosage, he complained of strange feelings after his evening does of aripiprazole (ie, he thought that somebody teased him). We increased the aripiprazole dosage to 25 mg/day for the irrational thought. But, he felt the condition worsen. After clarification, penile erection was noted. He stated that this would persist all day. Priapism was then diagnosed. He was bothered almost all day, especially when he lay down. We switched his antipsychotic to olanzapine 10 mg/day. The priapism soon disappeared.

In this case, we found priapism was related to the dosage of aripiprazole. Priapism could occur in any age, but is especially common from 20–50 years of age.2 Sood and colleagues1 identified 50 case reports of priapism linked to aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone. The mechanism of priapism associated with antipsychotics is not clear, however, it is thought to be related to α1-adrenergic blockage mediated by the α1 receptors in the corpora cavernosa of the penis.1,3 Aripiprazole exhibits high affinity for D4 and D3 and 5-HT1A and 5-HT2A receptors, and moderate affinity for D4, 5-HT2C, and 5-HT7, α1-adrenergic and H1 receptors.4 In this case, priapism was not present as an adverse effect when the dosage of aripiprazole was <20 mg/day. Priapism only presented in high dosage of aripiprazole treatment (>20 mg/day). Dosage related priapism was suspected. There is low risk of priapism in patients treated with any dosage of aripiprazole. However, when the dosage of aripiprazole is increased, priapism should be reminded.

Sincerely,
Wen-Yu Hsu, MD
Nan-Ying Chiu, MD
Chieh-Hui Wang, MD
Cheng-Yeh Lin, MD

REFERENCES

Dr. Hsu attending in the Department of Psychiatry, Lu-Tung Branch of Changhua Christian Hospital; and trainee, Division of Mental Health and Addiction Medicine, Institute of Population Health Sciences of National Health Research Institutes. Dr. Chiu is Director, Department of Psychiatry of CCH League of Affiliated Hospitals; Superintendent, Lu-Tung Branch of Changhua Christian Hospital; Assistant Professor, Chung Shan Medical University; Assistant Professor, National Changhua University of Education; Assistant Professor, Chang Jung Christian University; Assistant Professor, National Pingtung University of Education; Superintendent, Taipei County Society of Psychiatry; Director, Taiwan Society Against Depression; Director, Taiwan Society of Addiction Science; Director, Taiwan Society of Suicidology; and Director, Taiwan Society of Biological and Neuropsychopharmacology. Dr. Wang is head of the Department of Psychiatry, Lu-Tung Branch of Changhua Christian Hospital, and Lecturer at Chang Jung Christian University. Dr. Lin is a resident in the Department of Psychiatry at Changhua Christian Hospital.

Faculty Disclosures: Dr. Hsu has received honoraria from Janssen-Cilag and Otsuka; and has received funding from AstraZeneca, GlaxoSmithKline, and Sanofi-Aventis; and he has participated in research collaboration with Janssen-Cilag, Lundbeck, MSD, and Otsuka. Dr. Chiu has received honoraria from Eli Lilly, Janssen-Cilag, Otsuka, Pfizer, and Sanofi-Aventis; has received funding from Otsuka to attend scientific meetings; has participated in research collaboration with Janssen-Cilag, Lundbeck, MSD and Otsuka. Dr. Wang has received honoraria from Eli Lilly, Janssen-Cilag, Pfizer, sanofi-aventis; has received funding from Otsuka and has participated in research collaboration with Janssen-Cilag, MSD, and Otsuka. Dr. Lin reports no affiliations with or financial interests in any organization that may pose a conflict of interest.

Submitted for publication: September 9, 2010. Accepted for publication: September 21, 2010. First published online: August 1, 2011.

Please direct all correspondence to: Nan-Ying Chiu, MD, Department of Psychiatry, Lu-Tung Branch of Changhua Christian Hospital, 886 Lu-Tung Road, Lu-Kang Town, Changhua County, Taiwan. Tel: 886-4-7769595 ext.1584, Fax: 886-4-77699780; E-mail: 4008508@ccch.org.tw.

https://doi.org/10.1017/S1092852912000351 Published online by Cambridge University Press